The purpose of this study is to see how well the experimental imaging agent 89Zr-DFO-HuMab-5B1 attaches to pancreatic tumors, and to find out whether PET/CT scans done with this imaging agent produce better images of cancer.

Start Date10 May 2021

Sponsor / Collaborator

Memorial Sloan Kettering Cancer Center

[+1]

NCT02687230 / TerminatedPhase 1

Phase 1 Study of 89Zr-DFO-HuMab-5B1 (MVT-2163) With HuMab-5B1 (MVT-5873) in Patients With Pancreatic Cancer or Other CA19-9 Positive Malignancies

Open label, nonrandomized, dose-escalation trial of MVT-2163 and MVT-5873 used in performing PET scans. The study is designed to determine the best time and dose of these agents that result in the best PET image of a tumor. Subjects will be seen on days 1, 2, 4, and 7 for imaging and a clinical assessment. The last study visit is on day 28.

Start Date11 Jul 2016

Sponsor / Collaborator

BioNTech Research & Development, Inc.

[+1]

100 Clinical Results associated with 89Zr-HuMab 5B1

100 Translational Medicine associated with 89Zr-HuMab 5B1

100 Patents (Medical) associated with 89Zr-HuMab 5B1

Literatures (Medical) associated with 89Zr-HuMab 5B1

01 Dec 2019·Clinical Cancer ResearchQ1 · MEDICINE

Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic Cancer

Q1 · MEDICINE

Article

Author: Pandit-Taskar, Neeta ; Scholz, Wolfgang ; Maffuid, Paul W. ; O'Reilly, Eileen M. ; Lewis, Jason S. ; Teng, Rebecca ; O'Donoghue, Joseph A. ; Lyashchenko, Serge K. ; Lohrmann, Christian ; Ruan, Shutian ; Carrasquillo, Jorge A. ; Weber, Wolfgang A.

AbstractPurpose:In patients with cancer who have an abnormal biomarker finding, the source of the biomarker in the bloodstream must be located for confirmation of diagnosis, staging, and therapy planning. We evaluated if immuno-PET with the radiolabeled high-affinity antibody HuMab-5B1 (MVT-2163), binding to the cancer antigen CA19-9, can identify the source of elevated biomarkers in patients with pancreatic cancer.Patients and Methods:In this phase I dose-escalating study, 12 patients with CA19-9–positive metastatic malignancies were injected with MVT-2163. Within 7 days, all patients underwent a total of four whole-body PET/CT scans. A diagnostic CT scan was performed prior to injection of MVT-2163 to correlate findings on MVT-2163 PET/CT.Results:Immuno-PET with MVT-2163 was safe and visualized known primary tumors and metastases with high contrast. In addition, radiotracer uptake was not only observed in metastases known from conventional CT, but also seen in subcentimeter lymph nodes located in typical metastatic sites of pancreatic cancer, which were not abnormal on routine clinical imaging studies. A significant fraction of the patients demonstrated very high and, over time, increased uptake of MVT-2163 in tumor tissue, suggesting that HuMab-5B1 labeled with beta-emitting radioisotopes may have the potential to deliver therapeutic doses of radiation to cancer cells.Conclusions:Our study shows that the tumor antigen CA19-9 secreted to the circulation can be used for sensitive detection of primary tumors and metastatic disease by immuno-PET. This significantly broadens the number of molecular targets that can be used for PET imaging and offers new opportunities for noninvasive characterization of tumors in patients.

100 Deals associated with 89Zr-HuMab 5B1

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pancreatic Cancer	Phase 1	-	Memorial Sloan Kettering Cancer Center	-
Pancreatic Cancer	Phase 1	-	MabVax Therapeutics, Inc.	-
Colorectal Cancer	Discovery	US	-	26 Jan 2019
Small Cell Lung Cancer	Discovery	US	-	31 Dec 2018
Bladder Cancer	Discovery	US	-	11 Dec 2018
Pancreatic Carcinoma	Discovery	US	BioNTech Research & Development, Inc.	11 Jul 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AACR2012	Not Applicable	Breast Cancer	-	Doxorubicin-loaded Zirconium Phosphate nanoparticles	tqaijmkhgo(bznxzebpec) = yzonindjcs fxodqwvcav (gyxnxdryfb ) View more	-	15 Apr 2012
				Zirconium Phosphate nanoparticles	tqaijmkhgo(bznxzebpec) = ublkgrwfjr fxodqwvcav (gyxnxdryfb ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis